BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27389715)

  • 1. Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.
    Kapralova K; Horvathova M; Pecquet C; Fialova Kucerova J; Pospisilova D; Leroy E; Kralova B; Milosevic Feenstra JD; Schischlik F; Kralovics R; Constantinescu SN; Divoky V
    Blood; 2016 Sep; 128(10):1418-23. PubMed ID: 27389715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline JAK2 E846D Substitution as the Cause of Erythrocytosis?
    Maaziz N; Garrec C; Airaud F; Bobée V; Contentin N; Cayssials E; Rimbert A; Aral B; Bézieau S; Gardie B; Girodon F
    Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary erythrocytosis, thrombocytosis and neutrophilia.
    Hong WJ; Gotlib J
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):95-106. PubMed ID: 25189721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.
    Arcasoy MO; Harris KW; Forget BG
    Exp Hematol; 1999 Jan; 27(1):63-74. PubMed ID: 9923445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
    Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
    Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.
    Arcasoy MO; Karayal AF
    Biochim Biophys Acta; 2005 Apr; 1740(1):17-28. PubMed ID: 15878737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
    J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).
    Bento C; Almeida H; Maia TM; Relvas L; Oliveira AC; Rossi C; Girodon F; Fernandez-Lago C; Aguado-Diaz A; Fraga C; Costa RM; Araújo AL; Silva J; Vitória H; Miguel N; Silveira MP; Martin-Nuñez G; Ribeiro ML
    Eur J Haematol; 2013 Oct; 91(4):361-8. PubMed ID: 23859443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel germline JAK2
    Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
    Am J Hematol; 2024 Jul; 99(7):1220-1229. PubMed ID: 38629639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state.
    Watowich SS; Xie X; Klingmuller U; Kere J; Lindlof M; Berglund S; de la Chapelle A
    Blood; 1999 Oct; 94(7):2530-2. PubMed ID: 10498627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
    Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
    Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.
    Perrotta S; Cucciolla V; Ferraro M; Ronzoni L; Tramontano A; Rossi F; Scudieri AC; Borriello A; Roberti D; Nobili B; Cappellini MD; Oliva A; Amendola G; Migliaccio AR; Mancuso P; Martin-Padura I; Bertolini F; Yoon D; Prchal JT; Della Ragione F
    PLoS One; 2010 Aug; 5(8):e12015. PubMed ID: 20700488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.